Suggestion of Tunisia's medical oncologist in the management of breast cancer during COVID-19 pandemic.
Antineoplastic Protocols
Betacoronavirus
Breast Neoplasms
/ epidemiology
COVID-19
Communicable Disease Control
/ methods
Coronavirus Infections
/ epidemiology
Female
Humans
Medical Oncology
/ trends
Neoplasm Staging
Organizational Innovation
Pandemics
/ prevention & control
Patient Care Management
/ methods
Pneumonia, Viral
/ epidemiology
Risk Adjustment
/ methods
SARS-CoV-2
Telemedicine
/ methods
Tunisia
/ epidemiology
COVID-19
Tunisia
breast cancer
chemotherapy
medical oncology
Journal
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
15
8
2020
medline:
24
10
2020
entrez:
15
8
2020
Statut:
ppublish
Résumé
Cancer patients are at higher risk to be infected with COVID-19 and to develop a more severe form. Breast cancer (BC) treatments, including chemotherapy (CT), targeted therapy and immunotherapy can weaken the immune system and possibly cause lung problems. For all these reasons Salah Azaiez Institute's department of Medical Oncology took drastic actions to protect patients. In this article we will discuss protocol adjustments taken during
Identifiants
pubmed: 32791938
doi: 10.1177/1078155220948943
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM